Rapid clinic growth, rising concern
A surge in private ketamine clinics over the last five years has reshaped how depression and other psychiatric conditions are treated, and clinicians say the pace of expansion has outstripped oversight. From a handful of practices to more than a thousand clinics nationwide, the market now includes walk-in infusion centers, subscription programs and telehealth companies offering at-home regimens. That rapid expansion has prompted alarm among addiction specialists and hospital physicians.
Patients reporting severe withdrawal and complications
Clinics and emergency rooms are starting to see a new pattern: people who began medically supervised ketamine treatments later reporting intense cravings, prolonged low mood, anxiety, and physical symptoms when they try to stop. A large survey of people with ketamine use disorder found that 71 percent reported cravings after cessation, while more than 60 percent reported persistent low mood and bladder problems. Clinicians say these symptoms can be distressing and, in some cases, disabling.
Urology and organ complications escalating
Urology units in several countries are documenting a spike in severe bladder and urinary complications linked to heavy ketamine use. Case series and hospital reports in late 2025 and early 2026 described growing numbers of young patients with painful bladder inflammation, blood in urine, and kidney problems that in some cases required surgical intervention. Specialists warn that these are not simple, short-lived side effects but often chronic conditions that demand long-term care.
Clinical evidence and biological risks
Longitudinal studies and systematic reviews indicate that repeated, high-dose ketamine exposure can be associated with structural and functional brain changes, especially among recreational users taking doses far above clinical recommendations. Research shows alterations in gray matter and connectivity in frontal and limbic regions after prolonged heavy use, findings that addiction physicians say help explain cognitive complaints patients report during and after treatment. Those studies do not mean brief, controlled therapeutic use is equivalent to heavy recreational use, but they underline the need for careful dosing and follow-up.
Regulatory gaps and expert calls for standards
Regulators have issued warnings about compounded and off-label ketamine formulations, noting risks when products are used outside tightly controlled settings. Medical societies and addiction experts are urging clearer standards for patient selection, monitoring, and tapering, and they recommend routine screening for signs of developing dependence. Clinicians emphasize informed consent that covers both short-term benefits and potential long-term harms.
What clinicians say about the path forward
Frontline physicians describe a paradox: ketamine can produce rapid relief for treatment-resistant depression and, in experimental settings, may ease opioid withdrawal, yet the same compound can cause persistent problems when misused or poorly monitored. Experts call for standardized protocols, mandatory reporting of adverse events, and more funded research into long-term outcomes. Until those measures arrive, the clinical community says caution and close follow-up are essential for anyone receiving repeated ketamine treatments.
Clinics, hospitals and regulators now face a choice that will shape care for thousands of patients: scale quickly without uniform safeguards, or slow expansion while building the infrastructure needed to detect and treat emerging addiction and organ complications. The medical consensus is converging on one point, clear and urgent, that care must be safer and more accountable.